Annual CFO
-$4.13 M
+$2.52 M+37.92%
December 1, 2023
Summary
- As of February 7, 2025, NBY annual cash flow from operations is -$4.13 million, with the most recent change of +$2.52 million (+37.92%) on December 1, 2023.
- During the last 3 years, NBY annual CFO has risen by +$590.00 thousand (+12.50%).
- NBY annual CFO is now -187.08% below its all-time high of $4.74 million, reached on December 31, 2006.
Performance
NBY Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$2.06 M
-$1.48 M-256.57%
September 1, 2024
Summary
- As of February 7, 2025, NBY quarterly cash flow from operations is -$2.06 million, with the most recent change of -$1.48 million (-256.57%) on September 1, 2024.
- Over the past year, NBY quarterly CFO has dropped by -$1.42 million (-219.04%).
- NBY quarterly CFO is now -179.51% below its all-time high of $2.59 million, reached on March 31, 2010.
Performance
NBY Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$4.80 M
-$1.42 M-41.77%
September 1, 2024
Summary
- As of February 7, 2025, NBY TTM cash flow from operations is -$4.80 million, with the most recent change of -$1.42 million (-41.77%) on September 1, 2024.
- Over the past year, NBY TTM CFO has dropped by -$55.00 thousand (-1.16%).
- NBY TTM CFO is now -336.83% below its all-time high of $2.03 million, reached on December 31, 2010.
Performance
NBY TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
NBY Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +37.9% | -219.0% | -1.2% |
| 3 y3 years | +12.5% | -20.8% | +17.1% |
| 5 y5 years | +25.8% | -20.8% | +17.1% |
NBY Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +55.1% | -256.6% | +52.3% | -41.8% | +51.1% |
| 5 y | 5-year | at high | +55.1% | -256.6% | +52.3% | -41.8% | +51.1% |
| alltime | all time | -187.1% | +77.7% | -179.5% | +62.0% | -336.8% | +74.7% |
NovaBay Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.06 M(+256.6%) | -$4.80 M(+41.8%) |
| Jun 2024 | - | -$578.00 K(-63.2%) | -$3.39 M(-25.0%) |
| Mar 2024 | - | -$1.57 M(+165.5%) | -$4.52 M(+9.3%) |
| Dec 2023 | -$4.13 M(-37.9%) | -$592.00 K(-8.4%) | -$4.13 M(-13.0%) |
| Sep 2023 | - | -$646.00 K(-62.1%) | -$4.75 M(-18.0%) |
| Jun 2023 | - | -$1.71 M(+43.7%) | -$5.79 M(+0.1%) |
| Mar 2023 | - | -$1.19 M(-1.8%) | -$5.78 M(-13.1%) |
| Dec 2022 | -$6.65 M(-27.6%) | -$1.21 M(-28.4%) | -$6.65 M(-31.8%) |
| Sep 2022 | - | -$1.69 M(-0.6%) | -$9.76 M(+2.3%) |
| Jun 2022 | - | -$1.70 M(-17.4%) | -$9.54 M(-2.9%) |
| Mar 2022 | - | -$2.06 M(-52.4%) | -$9.83 M(+6.9%) |
| Dec 2021 | -$9.19 M(+94.7%) | -$4.32 M(+194.1%) | -$9.19 M(+45.5%) |
| Sep 2021 | - | -$1.47 M(-26.1%) | -$6.32 M(+1.6%) |
| Jun 2021 | - | -$1.99 M(+40.0%) | -$6.22 M(+17.9%) |
| Mar 2021 | - | -$1.42 M(-1.8%) | -$5.28 M(+11.7%) |
| Dec 2020 | -$4.72 M(-40.5%) | -$1.45 M(+5.5%) | -$4.72 M(+0.3%) |
| Sep 2020 | - | -$1.37 M(+31.6%) | -$4.71 M(-2.7%) |
| Jun 2020 | - | -$1.04 M(+20.3%) | -$4.83 M(-13.2%) |
| Mar 2020 | - | -$865.00 K(-39.5%) | -$5.57 M(-29.7%) |
| Dec 2019 | -$7.93 M(+42.4%) | -$1.43 M(-4.7%) | -$7.93 M(-6.6%) |
| Sep 2019 | - | -$1.50 M(-15.7%) | -$8.49 M(-1.4%) |
| Jun 2019 | - | -$1.78 M(-44.8%) | -$8.61 M(+3.4%) |
| Mar 2019 | - | -$3.22 M(+61.6%) | -$8.32 M(+49.5%) |
| Dec 2018 | -$5.57 M(-11.2%) | -$1.99 M(+23.2%) | -$5.57 M(-14.4%) |
| Sep 2018 | - | -$1.62 M(+8.4%) | -$6.50 M(+41.3%) |
| Jun 2018 | - | -$1.49 M(+221.8%) | -$4.60 M(-2.7%) |
| Mar 2018 | - | -$464.00 K(-84.1%) | -$4.73 M(-24.6%) |
| Dec 2017 | -$6.27 M(-46.2%) | -$2.93 M(-1141.3%) | -$6.27 M(+75.9%) |
| Sep 2017 | - | $281.00 K(-117.4%) | -$3.56 M(-53.7%) |
| Jun 2017 | - | -$1.62 M(-19.3%) | -$7.69 M(-11.9%) |
| Mar 2017 | - | -$2.01 M(+811.8%) | -$8.73 M(-25.1%) |
| Dec 2016 | -$11.66 M(-37.2%) | -$220.00 K(-94.3%) | -$11.66 M(-26.8%) |
| Sep 2016 | - | -$3.85 M(+44.8%) | -$15.93 M(-1.8%) |
| Jun 2016 | - | -$2.66 M(-46.1%) | -$16.22 M(-14.6%) |
| Mar 2016 | - | -$4.93 M(+9.9%) | -$18.98 M(+2.3%) |
| Dec 2015 | -$18.56 M | -$4.49 M(+8.5%) | -$18.56 M(+1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$4.14 M(-23.7%) | -$18.21 M(+8.3%) |
| Jun 2015 | - | -$5.42 M(+20.4%) | -$16.82 M(+11.0%) |
| Mar 2015 | - | -$4.51 M(+8.9%) | -$15.15 M(+0.6%) |
| Dec 2014 | -$15.05 M(+16.1%) | -$4.14 M(+50.8%) | -$15.05 M(-3.4%) |
| Sep 2014 | - | -$2.75 M(-26.8%) | -$15.59 M(+2.2%) |
| Jun 2014 | - | -$3.75 M(-15.0%) | -$15.25 M(+11.4%) |
| Mar 2014 | - | -$4.42 M(-5.5%) | -$13.69 M(+5.6%) |
| Dec 2013 | -$12.97 M(+98.7%) | -$4.67 M(+94.3%) | -$12.97 M(+13.9%) |
| Sep 2013 | - | -$2.41 M(+9.6%) | -$11.39 M(+30.5%) |
| Jun 2013 | - | -$2.20 M(-40.5%) | -$8.73 M(+16.6%) |
| Mar 2013 | - | -$3.69 M(+19.3%) | -$7.48 M(+14.6%) |
| Dec 2012 | -$6.53 M(+107.8%) | -$3.10 M(-1300.0%) | -$6.53 M(+62.3%) |
| Sep 2012 | - | $258.00 K(-127.0%) | -$4.02 M(+15.0%) |
| Jun 2012 | - | -$954.00 K(-65.1%) | -$3.50 M(-40.7%) |
| Mar 2012 | - | -$2.74 M(+364.5%) | -$5.89 M(+87.6%) |
| Dec 2011 | -$3.14 M(-254.9%) | -$589.00 K(-175.4%) | -$3.14 M(+583.0%) |
| Sep 2011 | - | $781.00 K(-123.3%) | -$460.00 K(-69.3%) |
| Jun 2011 | - | -$3.35 M(<-9900.0%) | -$1.50 M(+173.5%) |
| Mar 2011 | - | $16.00 K(-99.2%) | -$548.00 K(-127.0%) |
| Dec 2010 | $2.03 M(-223.1%) | $2.09 M(-911.2%) | $2.03 M(-1300.0%) |
| Sep 2010 | - | -$258.00 K(-89.2%) | -$169.00 K(-64.5%) |
| Jun 2010 | - | -$2.40 M(-192.6%) | -$476.00 K(-680.5%) |
| Mar 2010 | - | $2.59 M(-2592.3%) | $82.00 K(-105.0%) |
| Dec 2009 | -$1.65 M(-83.4%) | -$104.00 K(-81.6%) | -$1.65 M(-62.9%) |
| Sep 2009 | - | -$565.00 K(-69.3%) | -$4.45 M(-21.1%) |
| Jun 2009 | - | -$1.84 M(-313.6%) | -$5.64 M(-21.0%) |
| Mar 2009 | - | $862.00 K(-129.7%) | -$7.14 M(-28.2%) |
| Dec 2008 | -$9.94 M(+58.5%) | -$2.90 M(+65.5%) | -$9.94 M(+2.6%) |
| Sep 2008 | - | -$1.75 M(-47.5%) | -$9.69 M(+8.9%) |
| Jun 2008 | - | -$3.34 M(+71.9%) | -$8.90 M(+12.7%) |
| Mar 2008 | - | -$1.94 M(-26.8%) | -$7.89 M(+25.9%) |
| Dec 2007 | -$6.27 M(-232.2%) | -$2.66 M(+176.7%) | -$6.27 M(+73.5%) |
| Sep 2007 | - | -$960.00 K(-58.9%) | -$3.62 M(+36.2%) |
| Jun 2007 | - | -$2.33 M(+629.7%) | -$2.65 M(+729.7%) |
| Mar 2007 | - | -$320.00 K | -$320.00 K |
| Dec 2006 | $4.74 M(-246.9%) | - | - |
| Dec 2005 | -$3.23 M | - | - |
FAQ
- What is NovaBay Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals annual CFO year-on-year change?
- What is NovaBay Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly CFO year-on-year change?
- What is NovaBay Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals TTM CFO year-on-year change?
What is NovaBay Pharmaceuticals annual cash flow from operations?
The current annual CFO of NBY is -$4.13 M
What is the all time high annual CFO for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high annual cash flow from operations is $4.74 M
What is NovaBay Pharmaceuticals annual CFO year-on-year change?
Over the past year, NBY annual cash flow from operations has changed by +$2.52 M (+37.92%)
What is NovaBay Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of NBY is -$2.06 M
What is the all time high quarterly CFO for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high quarterly cash flow from operations is $2.59 M
What is NovaBay Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, NBY quarterly cash flow from operations has changed by -$1.42 M (-219.04%)
What is NovaBay Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of NBY is -$4.80 M
What is the all time high TTM CFO for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high TTM cash flow from operations is $2.03 M
What is NovaBay Pharmaceuticals TTM CFO year-on-year change?
Over the past year, NBY TTM cash flow from operations has changed by -$55.00 K (-1.16%)